PAREXEL Launches Next Generation Analytics Capabilities within Perceptive MyTrials® Platform
PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today launched the next generation of its Perceptive MyTrials® platform with advanced analytics capabilities. With the Perceptive MyTrials Analytics solution, clinical trial sponsors can now use a mobile-enabled, single entry-point to access predictive data analytics for multiple studies simultaneously. The solution offers real-time and aggregated analytics allowing sponsors and PAREXEL® clinical research professionals to detect key signals and trends. The Perceptive MyTrials Analytics solution also offers cross-sponsor viewing options for clients who need to evaluate data from multiple sponsors.
“As clinical studies become more complex, there is a growing need for real-time and standardized data and analytics from multiple studies,” said Xavier Flinois, President, PAREXEL Informatics. “Using the enhanced tools available with the Perceptive MyTrials Analytics solution, our clients can visualize trends across studies, garner reliable intelligence, and confidently make data-driven business decisions. This information will ultimately help reduce risk, increase clinical trial efficiency, and speed time to market for our clients and for patients.”